Clinical trials: Antibiotic Resistance, Bacterial
INFECTIONS, Skin and Subcutaneous Tissue Bacterial Infections
Study of Accuracy of New Diagnostic Technology to Guide Rapid Antibiotic Treatment for Serious Infections
This research will test a new ultra-rapid technology (called ID/AST Accelerate system) that uses a digital microscope to identify bacteria based on their growth patterns.
- Conditions
- INFECTIONS, Skin and Subcutaneous Tissue Bacterial Infections, Healthcare-associated Infection, Infection Due to Resistant Bacteria
- Trial name
- NCT02796716
- Testing
- Testing on new technology called Accelerate ID/AST system
- Where
- United States
- Volunteers
- 2,102 people
- Sponsor
- Denver Health and Hospital Authority
Bacterial Infections Oral
PLGA Nanoparticles Entrapping Ciprofloxacin to Treat E-Fecalis Infections in Endodontics
PLGA nanoparticles coated with Chitosan polymer were prepared and then incorporated in In -situ gel to be injected to root canals of patients suffered from bacterial infection of their endodontics.
- Trial name
- NCT05475444
- Testing
- Chitosan Coated PLGA nanoparticles entrapping Ciprofloxacin incorporated in smart gels, Ciprofloxacin paste and solution
- Where
- Egypt
- Volunteers
- 55 people
- Sponsor
- British University In Egypt
Sepsis
Evaluation of Usage Patterns and Outcomes in Patients Receiving Ceftolozane/Tazobactan (C/T) in Brazilian Hospitals
Ceftolozane/Tazobactan (C/T) is a recent option to manage multidrug resistant gram-negative infections in hospital patients. Despite several randomized controlled trials describing safety and efficacy of C/T, real world evidence…
- Trial name
- NCT05267483
- Testing
- No intervention
- Where
- Brazil
- Volunteers
- 100 people
- Sponsor
- D'Or Institute for Research and Education
Gram-Negative Bacterial Infections
Feasibility Studies to Inform Novel Proposals to Avert Community-Based Antimicrobial Resistance Spread
There are many bacteria that naturally live in our gut and are essential for good health. These bacteria have a variety of helpful functions, such as aiding digestion, synthesizing vitamins, repressing the growth of harmful…
- Trial name
- NCT02666274
- Where
- United Kingdom
- Volunteers
- 45 people
- Sponsor
- Guy's and St Thomas' NHS Foundation Trust
Drug Resistance, Multiple, Bacterial Infections
Prediction of Multidrug-resistant Bacterial Infection in Patients with Cirrhosis
The aim of this study is to identify predictive factors of infections caused by multidrug-resistant organisms in patients with cirrhosis and to develop and validate (internally and externally) a predictive model that might be…
- Conditions
- Drug Resistance, Multiple, Bacterial Infections, Liver Cirrhosis
- Trial name
- NCT05641025
- Where
- Argentina
- Volunteers
- 1,774 people
- Sponsor
- Hospital Italiano de Buenos Aires
Escherichia Coli; Infection, Intestinal
Study of the Ecological and Evolutionary Dynamics of Escherichia Coli in the Digestive Commensal Flora
Escherichia coli (E. coli) poses a major public health problem. E. coli is not only a commensal of the digestive tract but also a major opportunistic pathogen, first cause of urinary tract infections, first cause of bacteremia.
- Trial name
- EVE (NCT05153824)
- Where
- 2 sites in France
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Antibiotic Resistance, Enterobacteriaceae Infections
Genomic and Phenotypic Diversity of Carbapenemase-producing Escherichia Coli Strains Circulating in Southern France
Carbapenemase-producing Enterobacteriaceae (CPE) are classified as emerging Highly Resistant Bacteria (eHRB) because they expose infected patients to the risk of treatment failure due to the strains' resistance to last-line…
- Conditions
- Antibiotic Resistance, Enterobacteriaceae Infections, Carbapenem-Resistant Enterobacteriaceae Infection, Colonization
- Trial name
- CARBACOLI (NCT07676513)
- Testing
- MultiLocus Sequence Typing
- Where
- France
- Volunteers
- 163 people
- Sponsor
- Centre Hospitalier Universitaire de Nīmes
Oral Bacterial Colonization, Oral Hygiene
Effects of Three Oral Hygiene Protocols on Oral Bacteria in Intensive Care Patients
Patients in intensive care may develop changes in the bacteria found in their mouths. Some of these bacteria can cause infections, and patients who cannot clean their own teeth depend on staff to provide oral care.
- Trial name
- NCT07868549
- Testing
- Mechanical Oral Hygiene, Chlorhexidine, Hexetidine
- Where
- Croatia
- Volunteers
- 86 people
- Sponsor
- University of Zagreb
Irritable Bowel Syndrome (IBS), Small Intestinal Bacterial Overgrowth Syndrome (SIBO)
Herbal Supplement (Biocidin REMOVE) for Bacterial Overgrowth in Irritable Bowel Syndrome
The goal of this clinical trial is to learn if an herbal supplement called Biocidin REMOVE can clear small intestinal bacterial overgrowth (SIBO) in adults with irritable bowel syndrome (IBS).
- Trial name
- NCT07768267
- Testing
- Biocidin REMOVE
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Johns Hopkins University
Helicobacter Infections
Efficacy and Safety of Quadruple Therapy in Eradication of H. Pylori: A Comparison to Triple Therapy
This study aims at evaluating efficacy and safety of quadruple therapy (bismuth, metronidazole, tetracycline and omeprazole: OBMT) vs triple therapy (amoxicillin, clarithromycin and omeprazole: OAC) in H. Pylori eradication.
- Trial name
- NCT00669955
- Testing
- Omeprazole, amoxicillin, clarithromycin, Pylera (Bismuth subcitrate potassium, metronidazole, tetracycline) given in combination with omeprazole
- Where
- United Kingdom
- Volunteers
- 440 people
- Sponsor
- Forest Laboratories
Multi-antibiotic Resistance
Screening of Multidrug Resistant Bacteria, and the Clinical Implication for the Patient
The goal of this observational study is to evaluate the screening for multidrug resistant bacteria in patients admitted to hospitals in Scania.
- Trial name
- NCT06370299
- Testing
- (exposure of) MDR carriage
- Volunteers
- 10,000 people
- Sponsor
- Region Skane
Gonorrhoea
Rapid Diagnosis of Antibiotic Resistance in Gonorrhoea
The purpose of this study is to develop a laboratory-based assay that will be a real-time PCR test to detect the organism N. gonorrhoeae and its most important genetic markers of antimicrobial resistance.
- Trial name
- RaDAR-Go (NCT02350907)
- Where
- 3 sites in Switzerland
- Volunteers
- 261 people
- Sponsor
- University of Bern
Staphylococcal Infection
Strategies Using Off-Patent Antibiotics for Methicillin Resistant S. Aureus "STOP MRSA"
The purpose of this study is to determine the optimal outpatient treatment strategy of uncomplicated skin and soft tissue infection (SSTI) in areas of the United States where the prevalence of Community-Acquired…
- Trial name
- NCT00729937
- Testing
- Cephalexin, Clindamycin, Trimethoprim-sulfamethoxazole
- Where
- 5 sites in United States
- Volunteers
- 2,265 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Cirrhosis
Study Of Bacterial/Fungal Infections in Hospitalized Patients With Liver Cirrhosis in China
This is a national, investigator-initiated, multicenter, prospective, observational, web-based registry in hospitalized patients with cirrhosis across China.
- Trial name
- SONIC (NCT03676777)
- Where
- 23 sites in China
- Volunteers
- 1,232 people
- Sponsor
- Ruijin Hospital
Resistance Bacterial, Increased Drug Resistance
Decreasing Irrational Antimicrobial Use in Bangladesh: A Digital Intervention Program
We developed 'SmartAMR', a digital pharmacy system featuring real-time records, symptom checks, telemedicine, counselling, and medication reminders.
- Conditions
- Resistance Bacterial, Increased Drug Resistance, Drug Resistance, Microbial
- Trial name
- SmartAMR (NCT06313619)
- Testing
- SmartAMR
- Where
- Bangladesh
- Volunteers
- 27 people, healthy volunteers welcome
- Sponsor
- Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh
Staphylococcus Aureus Infection
Staph Intervention for Effective Local Defense
Indigenous persons experience a high burden of Staphylococcus aureus (SA) invasive disease and skin and soft tissue infections. SA carriage on the skin is factor for development of SA infections.
- Trial name
- SHIELD (NCT06210594)
- Testing
- Mupirocin + Nozin + chlorhexidine gluconate, Education + Household supplies
- Where
- United States
- Volunteers
- 78 people
- Sponsor
- Johns Hopkins Bloomberg School of Public Health
Pneumonia, Pneumococcal, Community Acquired Infections
New Antibiotic to Treat Patients With Community-acquired Pneumonia Due to a Specific Bacteria (S. Pneumoniae Pneumonia)
This study will treat patients who have a community-acquired pneumonia that is due to a specific bacteria (S. pneumoniae)
- Conditions
- Pneumonia, Pneumococcal, Community Acquired Infections, Gram-positive Bacterial Infections
- Trial name
- NCT00035269
- Testing
- Antibiotic
- Where
- 46 sites in United States, Slovakia and 2 more
- Volunteers
- 230 people
- Sponsor
- Pfizer
Antimicrobial Resistance (AMR)
NCCR AntiResist:: New Approaches to Combat Antibiotic-resistant Bacteria
This is an explorative, mono-center study including prospectively collected patient samples from the University Hospital of Basel.
- Trial name
- AntiResist (NCT05017766)
- Testing
- analysis of antimicrobial resistance
- Where
- Switzerland
- Volunteers
- 8,000 people, healthy volunteers welcome
- Sponsor
- University Hospital, Basel, Switzerland
Bacteremia, Sepsis
Epidemiology and Determinants of Outcomes of Hospital Acquired Blood Stream Infections in the Intensive Care in Turkey
In this observational study, it is aimed to investigate the mortality and morbidity rates of hospital-acquired blood stream infections that are treated in intensive care units (ICU).
- Conditions
- Bacteremia, Sepsis, Hospital Acquired Condition
- Trial name
- NCT04304456
- Testing
- Treatment
- Volunteers
- 810 people
- Sponsor
- SCARE (Study group for carbapenem resistance)
Respiratory Tract Infections, Corona Virus Infection
Inhaled Gaseous Nitric Oxide (gNO) Antimicrobial Treatment of Difficult Bacterial and Viral Lung (COVID-19) Infections
Non tuberculous mycobacteria (NTM), Burkholdria spp, Aspergillus in the lung are almost impossible to eradicate with conventional antibiotics. In addition COVID-19 has know current treatment.
- Trial name
- NCT03331445
- Testing
- Nitric Oxide 0.5 % / Nitrogen 99.5 % Gas for Inhalation
- Where
- Canada
- Volunteers
- 13 people
- Sponsor
- Chris Miller